The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).

[1]  J. Katz,et al.  The North American Immune Tolerance Registry: Practices, Outcomes, Outcome Predictors , 2002, Thrombosis and Haemostasis.

[2]  B. Kroner,et al.  Analysis of the North American Immune Tolerance Registry (NAITR) 1993–1997: Current Practice Implications , 1999, Vox Sanguinis.

[3]  H. Lenk.  The German National Immune Tolerance Registry, 1997 Update , 1999, Vox Sanguinis.

[4]  E. Santagostino,et al.  Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention , 1999, British journal of haematology.

[5]  M. Mitchell,et al.  Immune Tolerance Therapy for Haemophilia A Patients with Acquired Factor VIII Alloantibodies: Comprehensive Analysis of Experience at a Single Institution , 1999, Thrombosis and Haemostasis.

[6]  J. Gill,et al.  Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors , 1998, Thrombosis and Haemostasis.

[7]  M. Levi,et al.  Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and Belgium. , 1998, The Netherlands journal of medicine.

[8]  J. Goudemand.  Pharmaco‐economic aspects of inhibitor treatment , 1998, European journal of haematology. Supplementum.

[9]  Shapiro,et al.  A randomized, double‐blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors , 1998 .

[10]  A D Shapiro,et al.  Prospective, Randomised Trial of Two Doses of rFVIIa (NovoSeven) in Haemophilia Patients with Inhibitors Undergoing Surgery , 1998, Thrombosis and Haemostasis.

[11]  C. Kessler,et al.  Management of haemophilia B patients with inhibitors and anaphylaxis , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  V. Blanchette,et al.  Platelet activation induced by porcine factor VIII (HYATE:C) , 1998, American journal of hematology.

[13]  J. Lusher,et al.  Clinical experience with recombinant factor VIIa. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[14]  C. Négrier,et al.  The Treatment of Bleeding in Acquired Haemophilia with Recombinant Factor VIIa: A Multicentre Study , 1997, Thrombosis and Haemostasis.

[15]  D. S. Houston,et al.  Continuous infusion of porcine factor VIII in the management of patients with factor VIII inhibitors , 1997, American journal of hematology.

[16]  S. Follin,et al.  Acute Pain Management: Operative or Medical Procedures and Trauma , 1997, The Annals of pharmacotherapy.

[17]  S. Béguin,et al.  Thrombin, Fibrin and Platelets: a Resonance Loop in which von Willebrand Factor is a Necessary Link , 1997, Thrombosis and Haemostasis.

[18]  C. Rothschild,et al.  Multicenter Retrospective Study on the Utilization of FEIBA in France in Patients with Factor VIII and Factor IX Inhibitors , 1997, Thrombosis and Haemostasis.

[19]  I. Warrier,et al.  F, Spiro I: Posttransplantation lymphoproliferative disorders in solid Nephrotic Syndrome as a Complication of Immune Tolerance in Hemophilia B , 1997 .

[20]  J. Montoro,et al.  Comparative study of four different pharmacokinetic computer programs: case study of a factor VIII preparation , 1997, European Journal of Clinical Pharmacology.

[21]  E. Gomperts,et al.  Pharmacokinetic In Vivo Comparison Using 1-Stage and Chromogenic Substrate Assays with Two Formulations of Hemofil-M , 1996, Thrombosis and Haemostasis.

[22]  J. Fox.  Platelet activation: new aspects. , 1996, Haemostasis.

[23]  S. Schulman,et al.  Cyclosporine Therapy for Acquired Factor VIII Inhibitor in a Patient with Systemic Lupus Erythematosus , 1996, Thrombosis and Haemostasis.

[24]  G. Savidge,et al.  NovoSeven (recombinant factor VIIa) in centeral nervous systems bleeds. , 1996, Haemostasis.

[25]  R. Bech.  Recombinant factor VIIa in joint and muscle bleeding episodes. , 1996, Haemostasis.

[26]  S. Schulman,et al.  Feasibility of Using Recombinant Factor VIIa in Continuous Infusion , 1996, Thrombosis and Haemostasis.

[27]  C. Hay,et al.  Recommendations for the treatment of factor VIII inhibitors: from the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party. , 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[28]  E. Berntorp,et al.  Immune Tolerance and the Immune Modulation Protocol , 1996, Vox sanguinis.

[29]  J. Katz.  Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large‐scale North American survey , 1996, Haemophilia : the official journal of the World Federation of Hemophilia.

[30]  S. Ennis,et al.  Cloning of the bovine activin receptor type II gene (ACVR2) and mapping to chromosome 2 (BTA2). , 1996, Cytogenetics and cell genetics.

[31]  U. Hedner.  Dosing and monitoring NovoSeven treatment. , 1996, Haemostasis.

[32]  P. Mannucci,et al.  Safety Profile of Porcine Factor VIII and Its Use as Hospital and Home-Therapy for Patients with Haemophilia-A and Inhibitors: the Results of An International Survey , 1996, Thrombosis and Haemostasis.

[33]  E. Scheibel,et al.  Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. , 1996, Haemostasis.

[34]  J. Lusher.  Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. , 1996, Haemostasis.

[35]  H. M. van den Berg,et al.  Low-dose immune tolerance induction in hemophilia A patients with inhibitors. , 1995, Blood.

[36]  C. Kessler,et al.  A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. , 1995, Blood.

[37]  M. van den Berg,et al.  The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability , 1995, Thrombosis and Haemostasis.

[38]  G. Auerswald,et al.  Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow‐up , 1995, Haemophilia : the official journal of the World Federation of Hemophilia.

[39]  P. Roberts.  Virological safety of the purified factor IX concentrate, Replenine , 1995, Haemophilia : the official journal of the World Federation of Hemophilia.

[40]  G. Mariani,et al.  Immune Tolerance in Hemophilia-Principal Results from the International Registry , 1994, Thrombosis and Haemostasis.

[41]  J. Lusher,et al.  Use of prothrombin complex concentrates in management of bleeding in hemophiliacs with inhibitors--benefits and limitations. , 1994, Seminars in hematology.

[42]  E. Gordon,et al.  Continuous infusion of monoclonal antibody‐purified factor VIII: Rational approach to serious hemorrhage in patients with allo‐/autoantibodies to factor VIII , 1994, American journal of hematology.

[43]  A. Rademaker,et al.  A Prospective, Randomized Trial of Prednisone and Cyclophosphamide in the Treatment of Patients with Factor VIII Autoantibodies , 1993, Thrombosis and Haemostasis.

[44]  S. Arkin,et al.  Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A: Safety, Efficacy, and Development of Inhibitors , 1993 .

[45]  M. Hilgartner,et al.  Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII , 1993, The Lancet.

[46]  W. Kane,et al.  DDAVP in acquired hemophilia a: Case report and review of the literature , 1993, American journal of hematology.

[47]  M. Torchet,et al.  Comparison of Anti‐Human and Anti‐Porcine Factor VIII Inhibitor Levels in 63 Patients with Severe Haemophilia A , 1993, Vox sanguinis.

[48]  F. Rosendaal,et al.  A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group. , 1993, Blood.

[49]  E. Santagostino,et al.  Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors. , 1993, Seminars in hematology.

[50]  M. Magnifico,et al.  Continuous infusion of porcine factor VIII for the treatment of patients with factor VIII inhibitors. , 1993, Seminars in hematology.

[51]  C. Kessler,et al.  Use of porcine factor VIII in the treatment of patients with acquired hemophilia. , 1993, Blood.

[52]  L. Struillou,et al.  Acquired Haemophilia and Rheumatoid Arthritis: Success of Immunoglobulin Therapy , 1993, Journal of internal medicine.

[53]  S. Arkin,et al.  Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. , 1993, The New England journal of medicine.

[54]  J. Vermylen,et al.  A Higher than Expected Incidence of Factor VIII Inhibitors in Multitransfused Haemophilia A Patients Treated with an Intermediate Purity Pasteurized Factor VIII Concentrate , 1993, Thrombosis and Haemostasis.

[55]  W. Kreuz,et al.  Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs , 1992, The Lancet.

[56]  M. Morfini,et al.  The Design and Analysis of Half-Life and Recovery Studies for Factor VIII and Factor IX , 1991, Thrombosis and Haemostasis.

[57]  F. Clerck,et al.  Production of thromboxane and prostaglandins in human blood in the presence of thromboxane synthase inhibitors: a comparison of RIA and GC/MS determinations , 1991, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[58]  H. Kingdon,et al.  A two-phase linear regression model for biologic half-life data. , 1990, The Journal of laboratory and clinical medicine.

[59]  D. Brettler,et al.  The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience. , 1989, Archives of internal medicine.

[60]  K. Rák,et al.  Cyclosporin treatment of a woman with acquired haemophilia due to factor VIII:C inhibitor. , 1989, Postgraduate medical journal.

[61]  A. Y. Chiu,et al.  Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. , 1989, Annals of internal medicine.

[62]  D. Siegel,et al.  Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor. , 1988, The American journal of medicine.

[63]  A. van de Wiel,et al.  A patient with a spontaneous factor VIII:C autoantibody: successful treatment with cyclosporine. , 1988, Transplantation proceedings.

[64]  E. Berntorp,et al.  Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. , 1988, The New England journal of medicine.

[65]  H. Kwaan,et al.  An Acquired Factor VIII Inhibitor Responsive to High-Dose Gamma Globulin , 1987, Thrombosis and Haemostasis.

[66]  J. M. Matthews,et al.  Acquired haemophilia and rheumatoid arthritis. , 1987, British journal of rheumatology.

[67]  C. Kitchens,et al.  Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. , 1987, Archives of internal medicine.

[68]  G. Mariani,et al.  Inhibitor to factor VIII in a non-haemophilic patient: evaluation of the response to DDAVP and the in vitro kinetics of factor VIII. A case report. , 1987, Nouvelle revue francaise d'hematologie.

[69]  P. Mannucci,et al.  Von Willebrand factor contaminating porcine factor VIII concentrate (Hyate: C) causes platelet aggregation , 1986, British journal of haematology.

[70]  H. Kjellman.  Calculations of factor VIII in vivo recovery and half-life. , 2009, Scandinavian journal of haematology. Supplementum.

[71]  M. Kazatchkine,et al.  ANTI-IDIOTYPIC SUPPRESSION OF AUTOANTIBODIES TO FACTOR VIII (ANTIHAEMOPHILIC FACTOR) BY HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN , 1984, The Lancet.

[72]  P. Mannucci,et al.  Use of Porcine Factor VIII in the Management of Seventeen Patients with Factor VIII Antibodies , 1984, Thrombosis and Haemostasis.

[73]  Brackmann Hh.  Induced immunotolerance in factor VIII inhibitor patients. , 1984 .

[74]  E. Tuddenham,et al.  Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII. , 1984, Blood.

[75]  P. Levine,et al.  Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. , 1983, Blood.

[76]  A. Bloom,et al.  Human factor IX inhibitors: immunochemical characteristics and treatment with activated concentrate. , 1983, Clinical and laboratory haematology.

[77]  G. Knatterud,et al.  The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. , 1983, Blood.

[78]  N. Ewing,et al.  In vitro detection of mild inhibitors to factor VIII in hemophilia. , 1982, American journal of clinical pathology.

[79]  H. V. van Houwelingen,et al.  The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. , 1981, The New England journal of medicine.

[80]  J. Lewis,et al.  Corticosteroid Therapy for Acquired F VIII:C Inhibitors , 1981, British journal of haematology.

[81]  K. Lechner,et al.  A Survey of 215 Non-Hemophilic Patients with Inhibitors to Factor VIII , 1981, Thrombosis and Haemostasis.

[82]  S. Shapiro,et al.  Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. , 1980, The New England journal of medicine.

[83]  C. Kasper,et al.  Detection of factor VIII inhibitors with the partial thromboplastin time. , 1977, Blood.

[84]  D. Green,et al.  A More Uniform Measurement of Factor VIII Inhibitors , 1975, Thrombosis and Haemostasis.

[85]  D. Jackson,et al.  CIRCULATING ANTICOAGULANTS: A STUDY OF 40 CASES AND A REVIEW OF THE LITERATURE , 1961, Medicine.